Literature DB >> 23589031

VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation.

Jan Sperveslage, Midea Gierke, David Capper, Jürgen Honegger, Bence Sipos, Rudi Beschorner, Jens Schittenhelm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23589031     DOI： 10.1007/s00401-013-1118-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  11 in total

1.  BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

Authors:  Bette K Kleinschmidt-DeMasters; Dara L Aisner; Nicholas K Foreman
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

2.  Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.

Authors:  Jerzy Lasota; Artur Kowalik; Bartosz Wasag; Zeng-Feng Wang; Anna Felisiak-Golabek; Tiffany Coates; Janusz Kopczynski; Stanislaw Gozdz; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

3.  Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.

Authors:  Cristiane M Ida; Julie A Vrana; Fausto J Rodriguez; Mark E Jentoft; Alissa A Caron; Sarah M Jenkins; Caterina Giannini
Journal:  Acta Neuropathol Commun       Date:  2013-05-30       Impact factor: 7.801

4.  BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.

Authors:  Sarah Jane Larkin; Veronica Preda; Niki Karavitaki; Ashley Grossman; Olaf Ansorge
Journal:  Acta Neuropathol       Date:  2014-04-09       Impact factor: 17.088

5.  Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.

Authors:  Felix Behling; Alonso Barrantes-Freer; Marco Skardelly; Maike Nieser; Arne Christians; Florian Stockhammer; Veit Rohde; Marcos Tatagiba; Christian Hartmann; Christine Stadelmann; Jens Schittenhelm
Journal:  Diagn Pathol       Date:  2016-06-27       Impact factor: 2.644

Review 6.  Recent advances in molecular pathology of craniopharyngioma.

Authors:  Sarah Larkin; Niki Karavitaki
Journal:  F1000Res       Date:  2017-07-24

7.  Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.

Authors:  Katerina Dvorak; Birte Aggeler; John Palting; Penny McKelvie; Andrew Ruszkiewicz; Paul Waring
Journal:  Pathology       Date:  2014-10       Impact factor: 5.306

8.  Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.

Authors:  Sabrina Rossi; Marta Sbaraglia; Marta Campo Dell'Orto; Daniela Gasparotto; Matilde Cacciatore; Elena Boscato; Valentina Carraro; Luisa Toffolatti; Giovanna Gallina; Monia Niero; Emanuela Pilozzi; Alessandra Mandolesi; Fausto Sessa; Aurelio Sonzogni; Cristina Mancini; Guido Mazzoleni; Salvatore Romeo; Roberta Maestro; Angelo P Dei Tos
Journal:  Oncotarget       Date:  2016-05-24

9.  BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.

Authors:  Zeynep Tosuner; Melin Özgün Geçer; Mustafa Aziz Hatiboğlu; Anas Abdallah; Seval Turna
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967

Review 10.  Histopathology of Parasellar Neoplasms.

Authors:  Emilija Manojlovic-Gacic; Elham Rostami; Niki Karavitaki; Olivera Casar-Borota
Journal:  Neuroendocrinology       Date:  2020-03-11       Impact factor: 4.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.